Heidelberg/Incheon, 15. September 2021. Molecular Health GmbH will collaborate with EONE-Diagnomics Genome Center Co. Ltd. (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. The collaboration is intended to establish leadership in the fast-growing precision medicine market for liquid biopsy. Therefore, the two partners combine two major proprietary technologies, Molecular Health’s MH Guide and EDGC’s ONCOCATCH-CDxTM. This allows comprehensive genomic tumor profiling to guide treatment in solid tumors.

“The cooperation between Molecular Health and EDGC connects two well-established players in the field of precision medicine and forms an alliance that has the potential to significantly improve diagnosis and tailored treatment of cancer patients”, says Stephan Hettich, SVP, Head of Sales & Business Development, APAC with Molecular Health. “We are very happy to have found a strong and experienced partner like EDGC to capture the Asian market together.”

EDGC is an international joint venture based in South Korea that develops leading-edge technology for genome analysis and precision as well as personalized medicine. With ONCOCATCH-CDx the research and development company developed a unique non-invasive biopsy for early diagnosis, companion diagnostics and monitoring of all-stage cancer. The test analyses circulating tumor DNA (ctDNA), which is released from cancer cells into the bloodstream, through next-generation sequencing technology and state-of-the-art in-house bioinformatics. This provides the basis for personalized medicine prescription and helps doctors and patients in the decision-making. The global life science journal GenomeWeb labeled ONCOCATCH as ‘one of the world’s best-advanced technologies for early cancer diagnosis.

As part of the cooperation, EDGC aims to utilize Molecular Health’s MH Guide, analysis software that supports oncologists and molecular pathologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex datasets readable, and automatically identify genetic variants that are relevant for the treatment of cancer patients.

“When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx, qualitative comprehensive genomic profiling results can be provided to guide treatment in solid tumors,” Jeong Yoo-seok, EDGC Global Business Department Team Leader, summarizes the collaboration. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.

Please note
On 13th October 2021, EGDC and Molecular Health will be hosting a joint a webinar to give further details on the collaboration and the future joint activities. Partners may register by contacting yubinakim@edgc.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

Kim Seung-Gyun
EONE-Diagnomics Genome Center
seongyun.kim@edgc.com
Tel.: +82 32713-2190

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About EONE-Diagnomics Genome Center:

EDGC is the international joint venture established in 2013 between EONE Laboratories and Diagnomics. EDGC has developed leading-edge technology for genome analysis through constant research and development and has established a business network to expand its influence on the global market. Because of that, EDGC diagnoses various diseases over the entire life cycle and provides clinical solution for precision and personalized medicine. As the global leader of genome business, EDGC has worked on global projects with the most influential BT and IT companies in the world such as Illumina and Microsoft.

Read more on www.edgc.com

Download pdf